Listen: An ominous biotech deal, vaccines for kids, & ‘breakthrough’ devices
Can buyouts be bad news? Why can’t Novavax meet a deadline? And what does “breakthrough” actually mean?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we delve into why the latest big biotech acquisition has ominous implications for the downtrodden sector. Then, STAT’s Mario Aguilar joins us to explain how a well-intentioned FDA program is benefiting companies over patients. We also discuss the latest pandemic news, including the ongoing debate over boosters and yet another delay for Novavax.
